These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27864694)

  • 1. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.
    Bear HD; Tang G; Rastogi P; Geyer CE; Zoon CK; Kidwell KM; Robidoux A; Baez-Diaz L; Brufsky AM; Mehta RS; Fehrenbacher L; Young JA; Senecal FM; Gaur R; Margolese RG; Adams PT; Gross HM; Costantino JP; Paik S; Swain SM; Mamounas EP; Wolmark N
    Ann Surg Oncol; 2017 Jul; 24(7):1853-1860. PubMed ID: 27864694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction.
    Kansal KJ; Dominici LS; Tolaney SM; Isakoff SJ; Smith BL; Jiang W; Brock JE; Winer EP; Krop IE; Golshan M
    Breast Cancer Res Treat; 2013 Sep; 141(2):255-9. PubMed ID: 24026859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
    Blum JL; Flynn PJ; Yothers G; Asmar L; Geyer CE; Jacobs SA; Robert NJ; Hopkins JO; O'Shaughnessy JA; Dang CT; Gómez HL; Fehrenbacher L; Vukelja SJ; Lyss AP; Paul D; Brufsky AM; Jeong JH; Colangelo LH; Swain SM; Mamounas EP; Jones SE; Wolmark N
    J Clin Oncol; 2017 Aug; 35(23):2647-2655. PubMed ID: 28398846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does neoadjuvant bevacizumab increase surgical complications in breast surgery?
    Golshan M; Garber JE; Gelman R; Tung N; Smith BL; Troyan S; Greenberg CC; Winer EP; Ryan P
    Ann Surg Oncol; 2011 Mar; 18(3):733-7. PubMed ID: 20882415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44).
    Gerber B; von Minckwitz G; Eidtmann H; Rezai M; Fasching P; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Solbach C; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Nekljudova V; Loibl S; Untch M
    Ann Surg Oncol; 2014 Aug; 21(8):2517-24. PubMed ID: 24740826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical site infection in immediate breast reconstruction: Does chemotherapy timing make a difference?
    Chattha AS; Cohen JB; Bucknor A; Chen AD; Tobias AM; Lee BT; Lin SJ
    J Surg Oncol; 2018 Jun; 117(7):1440-1446. PubMed ID: 29574751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical complications of skin sparing mastectomy and immediate prosthetic reconstruction after neoadjuvant chemotherapy for invasive breast cancer.
    Donker M; Hage JJ; Woerdeman LA; Rutgers EJ; Sonke GS; Vrancken Peeters MJ
    Eur J Surg Oncol; 2012 Jan; 38(1):25-30. PubMed ID: 21963981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
    Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
    von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
    N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction.
    Warren Peled A; Itakura K; Foster RD; Hamolsky D; Tanaka J; Ewing C; Alvarado M; Esserman LJ; Hwang ES
    Arch Surg; 2010 Sep; 145(9):880-5. PubMed ID: 20855759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.
    Cortés J; Caralt M; Delaloge S; Cortes-Funes H; Pierga JY; Pritchard KI; Bollag DT; Miles DW
    Eur J Cancer; 2012 Mar; 48(4):475-81. PubMed ID: 22196033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
    Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
    Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of skin-sparing mastectomy with immediate reconstruction in patients with Stage III breast cancer treated with neoadjuvant chemotherapy and postmastectomy radiation.
    Prabhu R; Godette K; Carlson G; Losken A; Gabram S; Fasola C; O'Regan R; Zelnak A; Torres M
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e587-93. PubMed ID: 22197232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Autologous Breast Reconstruction Complications by Type of Neoadjuvant Chemotherapy Regimen.
    Olawoyin OM; Mehta S; Chouairi F; Gabrick KS; Avraham T; Pusztai L; Alperovich M
    Plast Reconstr Surg; 2021 Dec; 148(6):1186-1196. PubMed ID: 34644277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
    Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
    Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
    Zielinski C; Lang I; Beslija S; Kahan Z; Inbar MJ; Stemmer SM; Anghel R; Vrbanec D; Messinger D; Brodowicz T
    Br J Cancer; 2016 Jan; 114(2):163-70. PubMed ID: 26657657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
    von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
    J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
    von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
    Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.